Protocol Ledger

NCT05587374 · Phase III · ACTIVE NOT RECRUITING

Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)

Interventional Phase III clinical trial protocol NCT05587374 sponsored by Sun Yat-sen University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-08-01 Enrollment: 490 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05587374
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)490 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05587374
Protocol FieldVerified Registry Value
NCT IdentifierNCT05587374
Consolidated Lead SponsorSun Yat-sen University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment490 participants (ESTIMATED)
Registered Start Date2023-08-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI